BioCentury | Oct 21, 2020
Product Development

UCSF’s virus-host protein interaction maps ID targets for COVID-19, future coronaviruses

...that outpatients who had recently begun taking indomethacin...
BioCentury | Mar 25, 2020
Product Development

Repurposing candidates for COVID-19 from UCSF, Aldeyra

...were Iclusig ponatinib from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK), a lymphoma drug against RIPK1; indomethacin...
BioCentury | Nov 17, 2017
Clinical News

IRX reports Phase IIa data for citoplurikin in SCCHN

...U.S. trial is evaluating twice-daily injections of citoplurikin for 10 days in combination with cyclophosphamide, indomethacin...
BioCentury | Aug 17, 2015
Company News

Iroko sales and marketing update

...Iroko launched Tivorbex indomethacin in the U.S. to treat mild to moderate acute pain in adults...
...mild to moderate acute pain in adults. The lower dose submicron formulation of the NSAID indomethacin...
BioCentury | Mar 3, 2014
Clinical News

Tivorbex indomethacin regulatory update

...FDA approved an NDA from Iroko for Tivorbex indomethacin to treat mild to moderate acute pain...
...treat mild to moderate acute pain. The product is a submicron formulation of the NSAID indomethacin...
...Iroko Pharmaceuticals LLC , Philadelphia, Pa. Product: Tivorbex indomethacin ( IP 940 ) (formerly Tiforbex , submicron indomethacin...
BioCentury | Feb 26, 2014
Company News

U.S. approval for Iroko's Tivorbex

...FDA approved an NDA from Iroko Pharmaceuticals LLC (Philadelphia, Pa.) for Tivorbex indomethacin (formerly Tiforbex...
...treat mild to moderate acute pain. The product is a submicron formulation of the NSAID indomethacin...
...Inc. (Philadelphia, Pa.). Iroko declined to provide pricing details and said it plans to launch Tivorbex...
BioCentury | Aug 1, 2013
Financial News

Iroko withdraws IPO

...million and been valued at $492.2 million. FDA is reviewing NDAs from Iroko for Tiforbex submicron indomethacin...
...submicron formulation of the NSAID diclofenac, and Tiforbex is a submicron formulation of the NSAID indomethacin...
BioCentury | Jul 22, 2013
Clinical News

Tiforbex submicron indomethacin regulatory update

...Iroko said FDA accepted for review an NDA for Tiforbex submicron indomethacin to treat mild to moderate...
...scientific literature or from previously approved products. Tiforbex is a submicron formulation of the NSAID indomethacin...
...from iCeutica Inc. (Philadelphia, Pa.). Iroko Pharmaceuticals LLC , Philadelphia, Pa. Product: Tiforbex submicron indomethacin ( IP 940...
BioCentury | Jul 19, 2013
Financial News

Iroko sets IPO range

...$145 million in the offering last month. FDA is reviewing NDAs from Iroko for Tiforbex submicron indomethacin...
...submicron formulation of the NSAID diclofenac, and Tiforbex is a submicron formulation of the NSAID indomethacin...
BioCentury | Jul 16, 2013
Top Story

FDA to review Iroko's Tiforbex

...Iroko Pharmaceuticals LLC (Philadelphia, Pa.) said FDA accepted for review an NDA for Tiforbex submicron indomethacin to...
...2014, though a specific date is not disclosed. Tiforbex is a nanoformulation of the NSAID indomethacin...
Items per page:
1 - 10 of 53